Jan 4, 2021 • 7:00 AM EST Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001
Dec 7, 2020 • 6:35 AM EST Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology